A step forward in the treatment of relapsed or refractory follicular lymphoma
Mené sur 488 patients atteints d'un lymphome folliculaire réfractaire ou récidivant (durée médiane de suivi : 14,8 mois), cet essai multicentrique de phase III évalue l'efficacité, du point de vue du taux de réponse globale et de la survie sans progression, et la toxicité de l'ajout de l'epcoritamab à un traitement combinant lénalidomide et rituximab
Follicular lymphoma remains an incurable malignancy characterised by successive relapses. Despite favourable initial responses to front-line therapy, most patients eventually relapse, and lymphoma or treatment-related complications remain the leading cause of death.1 Accumulating evidence shows that the duration of response shortens with each subsequent line of therapy, resulting in progressively reduced progression-free survival and overall survival after each line of treatment
The Lancet , commentaire, 2025